Experienced in X-Linked Spondyloepiphyseal Dysplasia Tarda

Kazuko Hasegawa

Sagamihara, JP 
Experienced in X-Linked Spondyloepiphyseal Dysplasia Tarda
Sagamihara, JP 
OverviewLocationsClinical Research

Overview

Kazuko Hasegawa practices in Sagamihara, Japan. Ms. Hasegawa is rated as an Experienced expert by MediFind in the treatment of X-Linked Spondyloepiphyseal Dysplasia Tarda. Her top areas of expertise are Movement Disorders, Parkinson's Disease, Corticobasal Degeneration, and Progressive Supranuclear Palsy.

Her clinical research consists of co-authoring 80 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of X-Linked Spondyloepiphyseal Dysplasia Tarda.

Gender
Female

Locations

Sagamihara, Japan
Other Locations
Kangawa, 2520315, Japan
Tokyo, Japan
Yokosuka, 2520392, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS)
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS)
Enrollment Status: Active_not_recruiting
Publish Date: August 17, 2025
Intervention Type: Drug
Study Drug: Tolebrutinib
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio®) in Participants With Relapsing Forms of Multiple Sclerosis
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio®) in Participants With Relapsing Forms of Multiple Sclerosis
Enrollment Status: Completed
Publish Date: July 02, 2025
Intervention Type: Drug
Study Drugs: Tolebrutinib, Teriflunomide HMR1726
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis
Enrollment Status: Completed
Publish Date: July 02, 2025
Intervention Type: Drug
Study Drug: Tolebrutinib
Study Phase: Phase 3
View 2 Less Clinical Trials

80 Total Publications

Efficacy and Safety of IncobotulinumtoxinA for Treatment of Sialorrhea: A Multicenter, Phase 3 Study in Japan.
Efficacy and Safety of IncobotulinumtoxinA for Treatment of Sialorrhea: A Multicenter, Phase 3 Study in Japan.
Journal: Movement disorders clinical practice
Published: March 19, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Hasegawa's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 28 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile